Zhao et al. found that EML4-ALK fusion gene is significantly higher in patients with III-IV stage NSCLC than with I-II stage NSCLC [58] and in patients with brain metastases, the fusion may occur in 3–7% patients [55]. This evidence concerns the gene ALK and non-small cell lung carcinoma.